81 – 90 of 102
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection : The randomized controlled SENOMAC trial
(
- Contribution to journal › Article
-
Mark
Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy
(
- Contribution to journal › Article
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffinblocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
-
Mark
Tumor tissue protein signatures reflect histological grade of breast cancer
2017) In PLoS ONE(
- Contribution to journal › Article
-
Mark
AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
(
- Contribution to conference › Abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials
(
- Contribution to journal › Scientific review
-
Mark
Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort
(
- Contribution to journal › Article
-
Mark
The accuracy of preoperative axillary nodal staging in primary breast cancer by ultrasound is modified by nodal metastatic load and tumor biology
(
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
(
- Contribution to journal › Article